Cosciens Biopharma (CSCI) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
17 Jun, 2026Opening remarks and agenda
Meeting opened with introductions of the board and explanation of virtual meeting procedures, including Q&A and voting protocols.
Agenda included presentation of financial statements, auditor appointment, board elections, and a special resolution on share consolidation and split.
Board and executive committee updates
Six directors were nominated for re-election, all confirmed their willingness to serve and were eligible under corporate bylaws.
Shareholder proposals
Special resolution proposed for a share consolidation (1 for 150) followed by a share split (50 for 1), with cash-out for holders of fewer than 150 shares at $1.60 per share.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Cosciens Biopharma
- Q2 2026 delivered higher sales, lower expenses, and a major turnaround in profitability.CSCI
Q2 2026 - Returned to profitability in Q1 2026, driven by discontinued operations and lower expenses.CSCI
Q1 2026 - Restructuring and subsidiary exit drove lower losses and improved cost structure in 2025.CSCI
Q4 2025 - Operating expenses fell 59% and net loss narrowed in Q3 2025 amid restructuring and Nasdaq delisting.CSCI
Q3 2025 - Q2 2025 saw revenue growth, cost cuts, Nasdaq delisting, and major leadership changes.CSCI
Q2 2025 - Q3 2024 net loss widened on higher R&D and merger costs; new product launches on track.CSCI
Q3 2024 - Revenue rose but net loss widened due to higher R&D and SG&A costs; DETECT trial data expected Q3.CSCI
Q2 2024 - Six directors elected, auditor reappointed, and company name change approved; no questions asked.CSCI
AGM 2024 - Revenue up 35% but net loss deepened as COSCIENS pivots to natural-based products.CSCI
Q4 2024